Aug. 18, 2025
WuXi XDC Continues to Deliver Robust Business Growth and Financial Results in 1H 2025, Strengthening Global CRDMO Leadership Position in Bioconjugates Industry
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
Press Releases
-
-
Aug. 08, 2025WuXi XDC Included in MSCI China All Share Index -
Aug. 05, 2025WuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity -
Jun. 22, 2025WuXi XDC 2025 Interim Results and Corporate Update Call -
Jun. 30, 2025WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing -
Mar. 20, 2025WuXi XDC Received Multiple Awards from 2025 Extel (previously “Institutional Investor”) Ranking in Diverse Categories -
Apr. 10, 2025WuXi XDC Granted ISO 22301 Certification -
Apr. 03, 2025WuXi XDC and Mabsoft Therapeutics Form Strategic Partnership to Accelerate Development of Next-Generation Immune-Stimulating Antibody Conjugates (ISACs) -
Mar. 24, 2025WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024